Lawsuit: Health Insurance Innovations Hid License Rejection from Investors
by Erin Shaak
Last Updated on May 8, 2018
Vigorito v. Health Insurance Innovations, Inc. et al.
Filed: September 13, 2017 ◆§ 8:17-cv-02845-SDM-JSS
Health Insurance Innovations, Inc., along with its CEO and CFO, has been named as a defendant in a lawsuit filed by a man who claims the company failed to disclose material information to stockholders regarding an insurance license application.
New York
Health Insurance Innovations, Inc., along with its CEO and CFO, has been named as a defendant in a proposed class action lawsuit filed by a man who claims the company failed to disclose material information to stockholders regarding an insurance license application. According to the suit, the defendants hid from investors that the health insurance company’s application for a third-party administrators (TPA) license in Florida had been denied due to “undisclosed legal actions” against certain company insiders. Furthermore, the defendants allegedly failed to warn stockholders that the denial of their Florida application could result in a “domino effect” that would cause the company to lose licenses in several other states.
According to the suit, SeekingAlpha.com published an article on September 11, 2017 about the rejection of the defendant’s license application and caused Health Insurance Innovations’ stock prices to drop 21.91 percent, damaging investors.
Hair Relaxer Lawsuits
Women who developed ovarian or uterine cancer after using hair relaxers such as Dark & Lovely and Motions may now have an opportunity to take legal action.
Read more here: Hair Relaxer Cancer Lawsuits
How Do I Join a Class Action Lawsuit?
Did you know there's usually nothing you need to do to join, sign up for, or add your name to new class action lawsuits when they're initially filed?
Read more here: How Do I Join a Class Action Lawsuit?
Stay Current
Sign Up For
Our Newsletter
New cases and investigations, settlement deadlines, and news straight to your inbox.
Before commenting, please review our comment policy.